358 related articles for article (PubMed ID: 25397996)
1. Suvorexant: something new for sleep?
Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
[TBL] [Abstract][Full Text] [Related]
2. Suvorexant for the treatment of insomnia.
Jacobson LH; Callander GE; Hoyer D
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
4. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
5. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant: a novel therapy for the treatment of insomnia.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
[TBL] [Abstract][Full Text] [Related]
9. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
10. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
11. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Edmonds C; Swanoski M
Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
13. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
14. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
15. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
16. ACS chemical neuroscience molecule spotlight on Suvorexant.
Hopkins CR
ACS Chem Neurosci; 2012 Sep; 3(9):647-8. PubMed ID: 23024835
[TBL] [Abstract][Full Text] [Related]
17. Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
Asian J Psychiatr; 2017 Oct; 29():71-72. PubMed ID: 29061431
[No Abstract] [Full Text] [Related]
18. First-in-class insomnia drug on the brink of approval nod.
Osborne R
Nat Rev Drug Discov; 2013 Jul; 12(7):492-3. PubMed ID: 23812257
[No Abstract] [Full Text] [Related]
19. Small-molecule antagonists of the orexin receptors.
Christopher JA
Pharm Pat Anal; 2014; 3(6):625-38. PubMed ID: 25489915
[TBL] [Abstract][Full Text] [Related]
20. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
Born S; Gauvin DV; Mukherjee S; Briscoe R
Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
